Scaling AI-Powered Drug Discovery
Earendil Labs Raises $787M for AI Biologics
Sanofi and Pfizer-backed funds support AI-driven antibody development for autoimmune and inflammatory diseases.
A digital display in a laboratory shows a complex 3D rendering of a protein structure, representing AI-driven biologics design at Earendil Labs.
Photo: Avantgarde News
Earendil Labs secured $787 million in new financing to advance its AI-powered drug discovery platform [1]. The funding round received support from Sanofi and the Biotech Development Fund, which is backed by Pfizer and Hillhouse [1]. This capital will accelerate the development of antibodies and biologic therapies for autoimmune and inflammatory diseases [2]. The company currently manages a pipeline of more than 40 programs [1]. A primary focus includes a lead TL1A antibody that has recently entered Phase 2 clinical trials [3]. Earendil Labs aims to use its technology to streamline the design of complex biologics and improve therapeutic outcomes [2].
Editorial notes
Transparency note
Drafted with LLM; human-edited
- AI assisted
- Yes
- Human review
- Yes
- Last updated
Risk assessment
Reviewed for sourcing quality and editorial consistency.
Sources
- 1.↗
biospace.com
https://www.biospace.com/business/backed-by-sanofi-pfizer-earendil-bags-787m-for-ai-driven-biologics-design
- 2.↗
pharmaceutical-technology.com
https://www.pharmaceutical-technology.com/news/earendil-labs-787m-financing-ai-drug-discovery-development/
- 3.↗
pharmaphorum.com
https://pharmaphorum.com/news/earendil-raises-787m-lead-tl1a-antibody-starts-phase-2
Related stories
View all
Topics
About the author
Avantgarde News Desk covers scaling ai-powered drug discovery and editorial analysis for Avantgarde News.